Statement - CONSOLIDATED STATEMENTS OF INCOME - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Total revenue	$ 3,366.4	$ 2,964.5	$ 2,530.7
Total cost of revenue	1,716.9	1,451.2	1,225.0
Gross profit	1,649.5	1,513.3	1,305.7
Operating expenses:
Selling, general and administrative	893.8	729.4	607.4
Research and development	376.5	294.8	235.9
Other charges, net	126.1	52.2	29.7
Total operating expenses	1,396.4	1,076.4	873.0
Operating income	253.1	436.9	432.7
Bargain purchase gain and associated measurement period adjustments	(8.0)	144.1	0.0
Interest and other income (expense), net	(38.2)	(36.8)	(18.8)
Income before income taxes, equity in income (losses) of unconsolidated investees, net of tax, and noncontrolling interests in consolidated subsidiaries	206.9	544.2	413.9
Income tax provision	91.4	117.7	116.4
Equity in income (losses) of unconsolidated investees, net of tax	(1.7)	2.0	1.0
Consolidated net income	113.8	428.5	298.5
Net income attributable to noncontrolling interests in consolidated subsidiaries	0.7	1.3	1.9
Net income attributable to Bruker Corporation	$ 113.1	$ 427.2	$ 296.6
Net income attributable to Bruker Corporation shareholders per common share:
Basic	$ 0.76	$ 2.92	$ 2
Diluted	$ 0.76	$ 2.9	$ 1.99
Weighted average common shares outstanding:
Basic	149	146.4	148.6
Diluted	149.5	147.2	149.4
Product
Total revenue	$ 2,759.2	$ 2,457.6	$ 2,109.9
Total cost of revenue	1,364.5	1,165.2	984.0
Service and other revenue
Total revenue	607.2	506.9	420.8
Total cost of revenue	$ 352.4	$ 286.0	$ 241.0